Amarin Corp Plc (AMRN)

[ziploc_1]

Nsleven...re Brave study
"Primary Completion: "April 2021 [Anticipated] September 29, 2023 [Anticipated]
Study Completion: April 2021 [Anticipated] September 29, 2023 [Anticipated]"

The 'primary completion' date and the "study completion date' are now both both 'anticipated" to be September 29, 2023

My understanding of this change of dates means that this study was extended for over 2 years...Imho these scientists, who have dedicated themselves to finding solutions for Alzheimers, would not have extended the Brave study unless they were seeing some good results, but still waiting for statistical significance(which is unlikely to be achieved due to the small sample)...but, even without statistical significance, the FDA could approve a drug like Vascepa for AD, since it has a proven safety record... if it is case that the results are trending positive in a disease which has no really good alternative treatments.